iOnctura

iOnctura is a clinical-stage biopharmaceutical company developing a pipeline of precision oral small molecules to treat neglected and hard-to-treat cancers. The company targets the tumor-stroma-immune interface with therapies including an allosteric modulator of PI3Kδ, an autotaxin inhibitor, and a TGF-β pathway inhibitor. These treatments are designed to address tumors burdened by stroma and immune-mediated resistance while reducing toxicity compared to conventional therapies.